trending Market Intelligence /marketintelligence/en/news-insights/trending/UI1hM2kdfglKDkHfQN_4LQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Aerie Pharmaceuticals' glaucoma drug wins FDA panel backing

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aerie Pharmaceuticals' glaucoma drug wins FDA panel backing

A U.S. Food and Drug Administration advisory panel recommended the approval of Aerie Pharmaceuticals Inc.'s experimental glaucoma drug Rhopressa.

The panel voted 9-1 in favor of Rhopressa, concluding that its benefits outweigh its risks.

In addition, the panel voted unanimously in favor of the treatment being effective in lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Glaucoma is a condition that damages the optic nerve.

The regulator is expected to decide on the drug's approval Feb. 28, 2018. It is not required to act on the advice of its advisory panels, but generally does so.